const data = {
  id: 'philosophy',
  smallTitle: 'OUR INVESTMENT PHILOSOPHY',
  title: 'Now is the time to invest aggressively in biopharma.',
  description: 'We are in the early stages of a decades-long cycle of unprecedented innovation in medicine. By investing in development stage healthcare companies, we can simultaneously catalyze innovation that addresses unmet medical needs and capture key value inflections.',
  items: [
    {
      title: 'We are in a Golden Age for Therapeutics',
      description: 'Advances in genomics, computing power, and biomarkers have fueled the rise of precision and personalized medicine, while reducing the risks of drug development. As a result, early-stage biopharma companies can pursue big ideas more efficiently than ever, with increased odds of R&D success.'
    },
    {
      title: 'Innovation Drives Value',
      description: 'We understand the cost pressures faced by healthcare systems around the globe. Innovation must balance benefit to the patient, provider, and health system in order to generate meaningful long-term value. Thus, we are focused on major scientific advances, rather than “me too” products and other low value-creation strategies.'
    },
    {
      title: 'Science Guides Everything',
      description: 'The biopharma industry is driven by science, as are we. Focusing our due diligence on an in-depth understanding of the underlying science enables us to invest with a shared perspective.'
    },
    {
      title: 'Long-term Partnership is Key',
      description: 'Palkon manages a concentrated portfolio, which enables us to make meaningful time and capital commitments to our investments. We give each portfolio company our full attention, as well as access to our network and resources. We recognize that R&D is neither a short nor linear path, and have the experience and patience to be long-term partners.'
    }
  ]
}

export default data;